Catalyst Pharmaceuticals, Inc. CPRX
Set alert
31.49 USD 0.00 0.00%
As of Jul 15, 9:30 AM ET
31.49 Day range 31.49
20.66 52-week range 32.56
- YTD
- +34.92%
- 1 year
- +43.86%
- Open
- 31.49
- Prev close
- 31.49
- Mkt cap
- 3.85B
- Vol
- 0
- Avg vol
- 2.62M
- EPS
- 1.74
- P/E
- 17.49
- Div yield
- 0.00%
More statistics
- Low
- 31.49
- High
- 31.49
- Beta
- 0.74
- Inst. own
- 90.00%
- Dividend
- 0.00
- Earnings
- Aug 5, 2026
2Y chart
Events in this range
- Mar 3, 2025Rating: Baird · Outperform → Outperform
- May 7, 2025Earnings: 0.47; estimate 0.53; surprise -11.32%
- Aug 6, 2025Earnings: 0.43; estimate 0.58; surprise -25.86%
- Nov 5, 2025Earnings: 0.43; estimate 0.51; surprise -15.69%
- Nov 7, 2025Rating: Citigroup · Buy → Buy
- Feb 25, 2026Earnings: 0.42; estimate 0.42; surprise 0%
- Mar 3, 2026Rating: Citigroup · Buy → Buy
- May 7, 2026Downgrade: Stephens & Co. · Overweight → Equal-Weight
- May 8, 2026Downgrade: Citigroup · Buy → Neutral
- May 11, 2026Earnings: 0.52; estimate 0.64; surprise -18.75%
- May 28, 2026Downgrade: HC Wainwright & Co. · Buy → Neutral
Signals (80)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Jul 14, 2026 | 3 months ago |
| RSI: Overbought | Jul 2, 2026 | 4 months ago |
| MACD: Sell Signal | May 19, 2026 | 5 months ago |
| RSI: Overbought | May 5, 2026 | 6 months ago |
| RSI: Overbought | Apr 27, 2026 | 6 months ago |
| SMA: Bullish | Mar 31, 2026 | 7 months ago |
| SMA: Bearish | Mar 27, 2026 | 7 months ago |
| SMA: Bullish | Mar 26, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 26, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 12, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Feb 27, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 27, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 26, 2026 | 8 months ago |
| SMA: Bullish | Feb 13, 2026 | 8 months ago |
| SMA: Bearish | Feb 12, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 10, 2026 | 8 months ago |
| MACD: Buy Signal | Jan 21, 2026 | 9 months ago |
| SMA: Bullish | Jan 20, 2026 | 9 months ago |
| SMA: Bearish | Jan 15, 2026 | 9 months ago |
| SMA: Bullish | Jan 14, 2026 | 9 months ago |
| SMA: Bearish | Jan 13, 2026 | 9 months ago |
| SMA: Bullish | Jan 12, 2026 | 9 months ago |
| SMA: Bearish | Jan 6, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 30, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 16, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Nov 11, 2025 | 11 months ago |
| RSI: Overbought | Nov 11, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 10, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 6, 2025 | 12 months ago |
| SMA: Bullish | Oct 1, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 1, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 25, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 11, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 10, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 20, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 8, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 11, 2025 | 1 year ago |
| RSI: Oversold | Jul 7, 2025 | 1 year ago |
| RSI: Oversold | Jul 1, 2025 | 1 year ago |
| RSI: Oversold | Jun 25, 2025 | 1 year ago |
| SMA: Bearish | Jun 23, 2025 | 1 year ago |
| SMA: Bearish | Jun 13, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 12, 2025 | 1 year ago |
| MACD: Buy Signal | May 16, 2025 | 1 year ago |
| SMA: Bullish | May 9, 2025 | 1 year ago |
| SMA: Bearish | May 8, 2025 | 1 year ago |
| MACD: Sell Signal | May 8, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 24, 2025 | 1 year ago |
| SMA: Bearish | Apr 16, 2025 | 1 year ago |
| SMA: Bullish | Apr 14, 2025 | 1 year ago |
| SMA: Bearish | Apr 10, 2025 | 1 year ago |
| SMA: Bullish | Apr 9, 2025 | 1 year ago |
| SMA: Bearish | Apr 7, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 4, 2025 | 1 year ago |
| RSI: Overbought | Mar 24, 2025 | 1 year ago |
| SMA: Bullish | Mar 19, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 18, 2025 | 1 year ago |
| SMA: Bearish | Mar 4, 2025 | 1 year ago |
| SMA: Bullish | Feb 28, 2025 | 1 year ago |
| SMA: Bearish | Feb 20, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 7, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 10, 2025 | 1 year ago |
| SMA: Bullish | Jan 8, 2025 | 1 year ago |
| SMA: Bearish | Dec 27, 2024 | 1 year ago |
| SMA: Bullish | Dec 26, 2024 | 1 year ago |
| SMA: Bearish | Dec 18, 2024 | 1 year ago |
| SMA: Bullish | Dec 16, 2024 | 1 year ago |
| SMA: Bearish | Dec 12, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 3, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 2, 2024 | 1 year ago |
| SMA: Bullish | Nov 19, 2024 | 1 year ago |
| SMA: Bearish | Nov 15, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 14, 2024 | 1 year ago |
| RSI: Overbought | Nov 6, 2024 | 1 year ago |
| MACD: Buy Signal | Oct 15, 2024 | 2 years ago |
| RSI: Overbought | Aug 22, 2024 | 2 years ago |
| RSI: Overbought | Aug 20, 2024 | 2 years ago |
Key statistics
- Market cap
- 3.85B
- Enterprise value
- 3.10B
- Trailing P/E
- 17.49
- PEG ratio
- 2.07
- Price / sales
- 6.46
- Price / book
- 3.80
- Beta
- 0.74
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 37.08%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 23.65%
Analyst view
Price target (mean) —
Ratings (0m) 4 0 buy · 4 hold · 0 sell
- Strong buy0
- Buy0
- Hold4
- Sell0
- Strong sell0
Next earnings
Aug 5, 2026
Expected Aug 5, 2026. Consensus EPS estimate 0.73589.
Financials — quick view
CPRX Revenue — quarterly 149.39M
CPRX Net income — quarterly 63.73M
CPRX EPS — quarterly 0.52
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 5, 2026 | Jun 30, 2026 | 0.48 | — | — | — |
| May 11, 2026 | Mar 31, 2026 | 0.64 | 0.52 | -0.12 | -18.75% |
| Feb 25, 2026 | Dec 31, 2025 | 0.42 | 0.42 | 0.00 | 0.00% |
| Nov 5, 2025 | Sep 30, 2025 | 0.51 | 0.43 | -0.08 | -15.69% |
| Aug 6, 2025 | Jun 30, 2025 | 0.58 | 0.43 | -0.15 | -25.86% |
| May 7, 2025 | Mar 31, 2025 | 0.53 | 0.47 | -0.06 | -11.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 28, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| May 8, 2026 | Citigroup | down | Buy | Neutral |
| May 7, 2026 | Stephens & Co. | down | Overweight | Equal-Weight |
| Mar 3, 2026 | Citigroup | main | Buy | Buy |
| Nov 7, 2025 | Citigroup | main | Buy | Buy |
| Mar 3, 2025 | Baird | main | Outperform | Outperform |
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 182
- Website
- catalystpharma.com
News
- Chuck Royce's Second Quarter 2026 13F: Catalyst Pharmaceuticals Reduction Leads Portfolio Shifts
- California State Teachers Retirement System Acquires 30,717 Shares of Catalyst Pharmaceuticals, Inc. $CPRX
- Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst
- Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
- Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger
- Solaris Energy Infrastructure To Replace Catalyst Pharmaceuticals In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On July 15, 2026
- CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
- Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
- Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders?
- Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
Your note
Sign in to keep a note on CPRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DALY RICHARD J | Chief Executive Officer | Conversion of Exercise of derivative security | Jan 4, 2026 | 271,266 |
| DEL CARMEN JEFFREY | Officer | Conversion of Exercise of derivative security | Dec 28, 2025 | 14,337 |
| DENKHAUS DONALD A | Director | Conversion of Exercise of derivative security | Dec 28, 2025 | 498,773 |
| ELSBERND BRIAN D | Officer | Conversion of Exercise of derivative security | Dec 28, 2025 | 242,501 |
| INGENITO GARY | Officer | Conversion of Exercise of derivative security | May 13, 2025 | 68,873 |
| MCENANY PATRICK JAMES | Chairman of the Board | Conversion of Exercise of derivative security | Dec 28, 2025 | 4,171,560 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 15.34% | 18,774,530 | 591.21M | Mar 30, 2026 |
| State Street Corporation | 5.61% | 6,863,060 | 216.12M | Mar 30, 2026 |
| Vanguard Capital Management LLC | 4.18% | 5,122,666 | 161.31M | Mar 30, 2026 |
| American Century Companies Inc | 3.38% | 4,138,416 | 130.32M | Mar 30, 2026 |
| Deerfield Management Company, L.P | 3.22% | 3,943,600 | 124.18M | Mar 30, 2026 |
| Dimensional Fund Advisors LP | 2.80% | 3,429,615 | 108.00M | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.72% | 7,007,375 | 220.66M | May 30, 2026 |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 3.81% | 4,670,219 | 147.07M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.03% | 3,711,365 | 116.87M | Mar 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.43% | 2,974,227 | 93.66M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.25% | 2,759,811 | 86.91M | May 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.05% | 1,287,998 | 40.56M | Mar 30, 2026 |